Literature DB >> 8610978

Antigen-specific TGF-beta1 secretion with bovine myelin oral tolerization in multiple sclerosis.

H Fukaura1, S C Kent, M J Pietrusewicz, S J Khoury, H L Weiner, D A Hafler.   

Abstract

Multiple sclerosis is a presumed autoimmune disease, associated with inflammation in the CNS white matter, mediated by autoreactive T cells. We previously reported that oral myelin tolerization of relapsing-remitting MS patients resulted in fewer attacks, as compared to a placebo-fed group. Here, we examined whether oral tolerization with bovine myelin resulted in altered autoreactive T-cell populations or altered T-cell fraction. We generated 4,620 T-cell lines from 34 relapsing-remitting MS patients (17 were fed bovine myelin daily), and each line was examined for proliferation to MBP, PLP, and TT and for secretion of IL-4, IFN-gamma, and TGF-beta1. The frequency of TGF-beta1-secreting T-cell lines after MBP and PLP stimulation in fed patients was greater than that of nonfed patients. These experiments demonstrate that oral tolerization with autoantigen results in altered cytokine secretion in a human autoimmune disease with the generation of TGF-beta1-secreting T cells that may regulate the inflammatory response at the site of the demyelinating lesions in multiple sclerosis. These data provide the first evidence of antigen-specific modification of cytokine secretion in a human autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8610978     DOI: 10.1111/j.1749-6632.1996.tb21133.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  5 in total

1.  Immunoglobulin G subclass responses to Helicobacter pylori vary with age in populations with different levels of risk of gastric carcinoma.

Authors:  D I Campbell; M S Pearce; L Parker; J E Thomas; P B Sullivan; A Dale
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

2.  Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta.

Authors:  X Yang; J J Letterio; R J Lechleider; L Chen; R Hayman; H Gu; A B Roberts; C Deng
Journal:  EMBO J       Date:  1999-03-01       Impact factor: 11.598

3.  The role of regulatory T cell defects in type I diabetes and the potential of these cells for therapy.

Authors:  David Thomas; Paola Zaccone; Anne Cooke
Journal:  Rev Diabet Stud       Date:  2005-05-10

4.  A coimmunization vaccine of Aβ42 ameliorates cognitive deficits without brain inflammation in an Alzheimer's disease model.

Authors:  Shuang Wang; Yang Yu; Shuang Geng; Dongmei Wang; Li Zhang; Xiaoping Xie; Bing Wu; Chaofan Li; Hanqian Xu; Xiaolin Li; Yanxin Hu; Lianfeng Zhang; Christoph Kaether; Bin Wang
Journal:  Alzheimers Res Ther       Date:  2014-05-12       Impact factor: 6.982

Review 5.  Antigen-Specific Treatment Modalities in MS: The Past, the Present, and the Future.

Authors:  Judith Derdelinckx; Patrick Cras; Zwi N Berneman; Nathalie Cools
Journal:  Front Immunol       Date:  2021-02-19       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.